Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?
AuthorMileshkin, L; Shah, B; Michael, M
Source TitleChemotherapy Research and Practice
Medicine (St Vincent's)
Document TypeJournal Article
CitationsMileshkin, L., Shah, B. & Michael, M. (2012). Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?. Chemother Res Pract, 2012, pp.838509-. https://doi.org/10.1155/2012/838509.
Access StatusOpen Access
Open Access at PMChttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359779
There have been many exciting new breakthroughs in understanding tumour biology. This has opened up the possibility of personalized treatment for people with certain tumours. The epidermal growth factor receptor (EGFR) and K-ras are two such targets that can help classify tumours on a molecular basis and guide treatment decisions. However, there are still questions about how best to implement new molecular tests like these to characterize tumours in clinical practice. Potential obstacles include availability of good quality tissue specimens, access to the right test, and consensus about interpretation, funding, and availability. In this paper, we review these issues, by discussing these two examples in detail and suggest some actions for addressing potential barriers.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References